Tedizolid Phosphate
【Chemical Name】Tedizolid Phosphate
【Original】Cubist、Bayer
【Time to market】2014.06.20
【Patents expire】2024.12.16
【Dosage and Usage】Tablet: 200 mg,For injection: 200 mg, used for the treatment
of acute bacterial skin and skin structural infection (ABSSSI) caused by sensitive bacteria.
Tedizolid Phosphate
一、 Product Overview
Tedizolid Phosphate, an antibiotic developed by Cubist pharmaceuticals, USA, for the treatment of bacterial skin and skin structure infection, was approved by FDA on June 20, 2014, and the patent date of the compound expired on December 16, 2024.
二、Main products
Description | Structural Formula | CAS No. | Category |
Tedizolid Phosphate |  | 856867-55-5 | API |
(R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridine-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one |  | 856866-72-3 | intermediates |
5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine |  | 380380-64-3 | intermediates |
(R)-3-(4-bromo-3-fluorophenyl)-5-(hydroxymethyl)oxazolidin-2-one |  | 444335-16-4 | intermediates |
(R)-3-(3-fluorophenyl)-5-(hydroxymethyl)oxazolidin-2-one |  | 149524-42-5 | intermediates |
2-(2-methyl-2H-tetrazol-5-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine |  | 1056039-83-8 | intermediates |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.